21.10.2016 • News

Air Liquide Plans US Specialty Ingredients Plant

(c) Air Liquide
(c) Air Liquide

Two subsidiaries of French industrial gases giant Air Liquide have broken ground on a $60 million plant for cosmetic and pharmaceutical specialty ingredients being built on a greenfield site at Sandston in the US state of Virginia. The new production facility will be operated as a joint venture, Polykon Manufacturing, between the two Air Liquide group companies – healthcare specialty ingredients manufacturer Seppic and hygiene specialist Schülke. It is planned to start up in the first half of 2018 with around 20 employees and will supply the $10 billion global market for specialty personal care ingredients.

With the new facility, Air Liquide said the group will strengthen its proximity to customers in the US, which accounts for about 25% of the global market, while at the same time extending the specialist companies’ innovative potential and enlarging their industrial footprint. Both Seppic and Schülke have a long-time presence in the US. The former is present in more than 100 countries through its affiliates and network of distributors, the latter, which employs more than 900 employees worldwide, is present in 80 countries.

Meanwhile, Air Liquide said it has successfully completed the refinancing of its $13.4 billion acquisition of US rival Airgas through two bond issues and an equity increase. Integration of the new assets is proceeding according to plan, said, CEO Benoît Potier. Globally, the combined gases businesses are expected to generate annual sales of around $22 billion and supply more than over three million customers.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read